Tislelizumab‑induced psoriasis in a patient with hepatocellular carcinoma: A case report
Experimental and Therapeutic Medicine · 23.09.2026 · 32 (5) · 1-7
DOI: 10.3892/etm.2026.13314 ↗Kurz gefasst
Fallbericht in der Zeitschrift Experimental and Therapeutic Medicine, online erschienen am 23.09.2026. Verfasst von Zhaochen Sun und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu 210018, P.R. China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) are widely incorporated into first-line treatment regimens for advanced hepatocellular carcinoma (HCC). Nevertheless, the growing incidence of immune-related adverse events (irAEs), particularly dermatologic toxicities, poses a substantial challenge to the continuation of anticancer therapy. The present study describes a case of tislelizumab-associated psoriasis in a patient with hepatitis C virus (HCV)-related HCC, emphasizing the need for prompt recognition and individualized management. A 60-year-old man with stage IIIA HCC and chronic HCV infection developed progressively worsening erythematous plaques with scaling during the eighth cycle of tislelizumab plus bevacizumab. Histopathological examination of a skin biopsy supported a diagnosis of pustular psoriasis. A Naranjo Adverse Drug Reaction Probability Scale score of 7 suggested that tislelizumab was the probable causative agent. Because the patient had type 2 diabetes mellitus and declined systemic glucocorticoid treatment, tislelizumab was discontinued, and narrow-band ultraviolet B (NB-UVB) phototherapy was administered in combination with topical corticosteroids. The skin lesions markedly resolved with no recurrence during the 6-week follow-up period. To the best of our knowledge, this is the first report of NB-UVB phototherapy successfully treating ICI-induced psoriasis. This case underscores the need for close monitoring of cutaneous irAEs during ICI therapy and suggests that NB-UVB phototherapy may be an effective alternative to systemic corticosteroids for managing ICI-induced psoriasis, particularly in patients where preservation of antitumor immunity is desirable or systemic steroids are contraindicated. Regular multidisciplinary follow-up and individualized management of adverse events are essential for optimizing both oncological and dermatological outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu 210018, P.R. China.
- Department of Hematology and Oncology, 904 Hospital of People's Liberation Army Joint Logistic Support Force, Wuxi, Jiangsu 214000, P.R. China.
- Department of Dermatology and Venereology, 904 Hospital of PLA Joint Logistic Support Force, Wuxi, Jiangsu 214000, P.R. China.
Zitieren
APA
Sun, Z., Zhou, Y., Mei, Y., & Chen, Y. (2026). Tislelizumab‑induced psoriasis in a patient with hepatocellular carcinoma: A case report. Experimental and Therapeutic Medicine, 32(5), 1-7. https://doi.org/10.3892/etm.2026.13314
Vancouver
Sun Z, Zhou Y, Mei Y, Chen Y. Tislelizumab‑induced psoriasis in a patient with hepatocellular carcinoma: A case report. Experimental and Therapeutic Medicine. 2026;32(5):1-7. doi:10.3892/etm.2026.13314
BibTeX
@article{Sun2026,
author = {Sun, Zhaochen and Zhou, Yuqi and Mei, Yeliang and Chen, Yitian},
title = {Tislelizumab‑induced psoriasis in a patient with hepatocellular carcinoma: A case report},
journal = {Experimental and Therapeutic Medicine},
year = {2026},
volume = {32},
number = {5},
pages = {1--7},
doi = {10.3892/etm.2026.13314}
}
EUVIMED